GLP Winner is mentioned in
Find doctor-trusted weight loss
treatment options.
Cash pay and
insurance support

Brand Name Medication
Compare telehealth providers that take insurance and support prior authorization.
New cash-pay customers: $199/mo for the first 2 months, then $349/mo after. Offer ends March 31, 2026.
Avoid sketchy providers.
Online ads sometimes show unsafe providers...
Research peptides
Not prescribed by a doctor
Experimental medications
Unlicensed operations
Difficult cancellation
Misleading pricing
Help millions
make the right choice.
Share your experience on GLP Winner, where real reviews make a difference.
Robin Jackson ,
NJ
Shawn j Slavens ,
KS
Marcy hinz,
IA
Robin Jackson ,
NJ
Shawn j Slavens ,
KS
Marcy hinz,
IA
Robin Jackson ,
NJ
Shawn j Slavens ,
KS
Marcy hinz,
IA
Robin Jackson ,
NJ
Shawn j Slavens ,
KS
Marcy hinz,
IA
Shawn j Slavens ,
KS
A Smith,
IN
Jill,
PA
Shawn j Slavens ,
KS
A Smith,
IN
Jill,
PA
Shawn j Slavens ,
KS
A Smith,
IN
Jill,
PA
Shawn j Slavens ,
KS
A Smith,
IN
Jill,
PA
Barbara,
TX
Tawny,
CA
Barbara,
TX
Barbara,
TX
Tawny,
CA
Barbara,
TX
Barbara,
TX
Tawny,
CA
Barbara,
TX
Barbara,
TX
Tawny,
CA
Barbara,
TX
Andrea,
OH
Kim,
KY
Jeff,
MI
Andrea,
OH
Kim,
KY
Jeff,
MI
Andrea,
OH
Kim,
KY
Jeff,
MI
Andrea,
OH
Kim,
KY
Jeff,
MI
Michael,
GA
Aline ,
MO
SIMB,
CA
Michael,
GA
Aline ,
MO
SIMB,
CA
Michael,
GA
Aline ,
MO
SIMB,
CA
Michael,
GA
Aline ,
MO
SIMB,
CA
Rhonda Mariott ,
IN
Kristy,
AZ
Michelle ,
VA
Rhonda Mariott ,
IN
Kristy,
AZ
Michelle ,
VA
Rhonda Mariott ,
IN
Kristy,
AZ
Michelle ,
VA
Rhonda Mariott ,
IN
Kristy,
AZ
Michelle ,
VA
Marco,
OH
Prudhomme,
RI
Becka,
TX
Marco,
OH
Prudhomme,
RI
Becka,
TX
Marco,
OH
Prudhomme,
RI
Becka,
TX
Marco,
OH
Prudhomme,
RI
Becka,
TX
A Smith,
IN
Emily S,
IA
Colleen McAbee,
CA
A Smith,
IN
Emily S,
IA
Colleen McAbee,
CA
A Smith,
IN
Emily S,
IA
Colleen McAbee,
CA
A Smith,
IN
Emily S,
IA
Colleen McAbee,
CA
We don't sell these medications. We don't prescribe them.
We help you navigate the ecosystem.
Discover
glp-1 news.
Stay up to date with the latest news, research, and insights from the GLP-1 community.

















